The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected

Traditionally, phase II cancer trials test a binary endpoint formed from a dichotomisation of the continuous change in tumour size. Directly testing the continuous endpoint provides considerable gains in power, although also results in several statistical issues. One such issue is when complete resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Wason, James MS, Mander, Adrian P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668774/
https://www.ncbi.nlm.nih.gov/pubmed/22179821
http://dx.doi.org/10.1177/0962280211432192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668774/
https://www.ncbi.nlm.nih.gov/pubmed/22179821
http://dx.doi.org/10.1177/0962280211432192

Ejemplares similares